ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES
A certain success in the treatment of bronchial asthma is associated with the introduction of monoclonal antibodies into the treatment process. They made it possible to improve the control of the disease. A number of original genetically engineered biological drugs, such as benralizumab, reslizumab,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2021-08-01
|
| Series: | Фармация и фармакология (Пятигорск) |
| Subjects: | |
| Online Access: | https://www.pharmpharm.ru/jour/article/view/864 |
| _version_ | 1797874702879817728 |
|---|---|
| author | V. S. Krysanova E. D. Ermolaeva T. N. Ermolaeva M. V. Davydovskaya K. A. Kokushkin |
| author_facet | V. S. Krysanova E. D. Ermolaeva T. N. Ermolaeva M. V. Davydovskaya K. A. Kokushkin |
| author_sort | V. S. Krysanova |
| collection | DOAJ |
| description | A certain success in the treatment of bronchial asthma is associated with the introduction of monoclonal antibodies into the treatment process. They made it possible to improve the control of the disease. A number of original genetically engineered biological drugs, such as benralizumab, reslizumab, dupilumab, mepolizumab and omalizumab, are currently registered in Russia. In 2020, this list was supplemented by the first Russian biosimilar drug omalizumab – Genolar® (JSC Generium, Russia). High rates of the development of modern medicine are closely related to the use of biosimilars. The prescription of biosimilars today often makes it possible to provide a larger number of patients with modern drugs at lower costs.The aim of the study was a comprehensive pharmacoeconomic assessment of the application of the domestic biosimilar drug omalizumab in the treatment of patients suffering from moderate and severe atopic bronchial asthma.Materials and methods. At the first stage, an information search in the available databases (Cochrane Library, MedLine, Embase, eLIBRARY) was carried out. According to the results obtained, a meta-analysis (Agache I. et al.) was found out; within its framework, the efficacy and safety of the use of several monoclonal antibodies was assessed. Dupilumab was chosen as the reference drug. Pharmacoeconomic analyses were carried out using a “Cost-Minimization Analysis” (CMA) and a “Budget Impact Analysis” (BIA). Taking into account various options of bronchial asthma, the developed algorithm for providing medical care to adult patients with atopic asthma made it possible to assess the costs, including direct medical and indirect costs.Results. The cost analysis demonstrated the advantage of using the Russian biosimilar omalizumab in patients with atopic asthma compared to dupilumab due to financial savings of up to 40%. The Budget Impact Analysis showed that the use of the domestic biosimilar omalizumab, even taking into account the annual increase in the number of patients (8%), will save up to 109,641,409.64 rubles (or 3%) compared to the current practice.Conclusion. The use of the domestic biosimilar omalizumab in patients with moderate to severe atopic bronchial asthma is a clinically effective and economically justified approach to organizing medical care for adult patients in Russia. |
| first_indexed | 2024-04-10T01:36:12Z |
| format | Article |
| id | doaj.art-b52ae0d03a41448ea6d1e2b09244a8b2 |
| institution | Directory Open Access Journal |
| issn | 2307-9266 2413-2241 |
| language | Russian |
| last_indexed | 2024-04-10T01:36:12Z |
| publishDate | 2021-08-01 |
| publisher | Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute |
| record_format | Article |
| series | Фармация и фармакология (Пятигорск) |
| spelling | doaj.art-b52ae0d03a41448ea6d1e2b09244a8b22023-03-13T09:18:13ZrusVolgograd State Medical University, Pyatigorsk Medical and Pharmaceutical InstituteФармация и фармакология (Пятигорск)2307-92662413-22412021-08-019323524810.19163/2307-9266-2021-9-3-235-248392ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSESV. S. Krysanova0E. D. Ermolaeva1T. N. Ermolaeva2M. V. Davydovskaya3K. A. Kokushkin41. Государственное бюджетное учреждение Московской области «Научно-практический центр клинико-экономического анализа Министерства здравоохранения Московской области» 143403, Россия, Московская область, г. Красногорск, ул. Карбышева, 4А 2. Медицинский институт непрерывного образования Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет пищевых производств» 125080, Россия, г. Москва, Волоколамское шоссе, 11 3. Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет) 119991, Россия, г. Москва, ул. Трубецкая, 81. Государственное бюджетное учреждение Московской области «Научно-практический центр клинико-экономического анализа Министерства здравоохранения Московской области» 143403, Россия, Московская область, г. Красногорск, ул. Карбышева, 4А 2. Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет) 119991, Россия, г. Москва, ул. Трубецкая, 8Государственное бюджетное учреждение Московской области «Научно-практический центр клинико-экономического анализа Министерства здравоохранения Московской области» 143403, Россия, Московская область, г. Красногорск, ул. Карбышева, 4А1. Государственное бюджетное учреждение Московской области «Научно-практический центр клинико-экономического анализа Министерства здравоохранения Московской области» 143403, Россия, Московская область, г. Красногорск, ул. Карбышева, 4А 2. Федеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации 117997, Россия, г. Москва, ул. Островитянова, д. 11. Государственное бюджетное учреждение Московской области «Научно-практический центр клинико-экономического анализа Министерства здравоохранения Московской области» 143403, Россия, Московская область, г. Красногорск, ул. Карбышева, 4А 2. Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет) 119991, Россия, г. Москва, ул. Трубецкая, 8A certain success in the treatment of bronchial asthma is associated with the introduction of monoclonal antibodies into the treatment process. They made it possible to improve the control of the disease. A number of original genetically engineered biological drugs, such as benralizumab, reslizumab, dupilumab, mepolizumab and omalizumab, are currently registered in Russia. In 2020, this list was supplemented by the first Russian biosimilar drug omalizumab – Genolar® (JSC Generium, Russia). High rates of the development of modern medicine are closely related to the use of biosimilars. The prescription of biosimilars today often makes it possible to provide a larger number of patients with modern drugs at lower costs.The aim of the study was a comprehensive pharmacoeconomic assessment of the application of the domestic biosimilar drug omalizumab in the treatment of patients suffering from moderate and severe atopic bronchial asthma.Materials and methods. At the first stage, an information search in the available databases (Cochrane Library, MedLine, Embase, eLIBRARY) was carried out. According to the results obtained, a meta-analysis (Agache I. et al.) was found out; within its framework, the efficacy and safety of the use of several monoclonal antibodies was assessed. Dupilumab was chosen as the reference drug. Pharmacoeconomic analyses were carried out using a “Cost-Minimization Analysis” (CMA) and a “Budget Impact Analysis” (BIA). Taking into account various options of bronchial asthma, the developed algorithm for providing medical care to adult patients with atopic asthma made it possible to assess the costs, including direct medical and indirect costs.Results. The cost analysis demonstrated the advantage of using the Russian biosimilar omalizumab in patients with atopic asthma compared to dupilumab due to financial savings of up to 40%. The Budget Impact Analysis showed that the use of the domestic biosimilar omalizumab, even taking into account the annual increase in the number of patients (8%), will save up to 109,641,409.64 rubles (or 3%) compared to the current practice.Conclusion. The use of the domestic biosimilar omalizumab in patients with moderate to severe atopic bronchial asthma is a clinically effective and economically justified approach to organizing medical care for adult patients in Russia.https://www.pharmpharm.ru/jour/article/view/864бронхиальная астмабиоаналогомализумабдупилумабзатратыклинико-экономический анализ |
| spellingShingle | V. S. Krysanova E. D. Ermolaeva T. N. Ermolaeva M. V. Davydovskaya K. A. Kokushkin ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES Фармация и фармакология (Пятигорск) бронхиальная астма биоаналог омализумаб дупилумаб затраты клинико-экономический анализ |
| title | ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES |
| title_full | ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES |
| title_fullStr | ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES |
| title_full_unstemmed | ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES |
| title_short | ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES |
| title_sort | economic aspects of application of the russian biosimilar omalizumab in patients with atopic bronchial asthma of moderate to severe clinical courses |
| topic | бронхиальная астма биоаналог омализумаб дупилумаб затраты клинико-экономический анализ |
| url | https://www.pharmpharm.ru/jour/article/view/864 |
| work_keys_str_mv | AT vskrysanova economicaspectsofapplicationoftherussianbiosimilaromalizumabinpatientswithatopicbronchialasthmaofmoderatetosevereclinicalcourses AT edermolaeva economicaspectsofapplicationoftherussianbiosimilaromalizumabinpatientswithatopicbronchialasthmaofmoderatetosevereclinicalcourses AT tnermolaeva economicaspectsofapplicationoftherussianbiosimilaromalizumabinpatientswithatopicbronchialasthmaofmoderatetosevereclinicalcourses AT mvdavydovskaya economicaspectsofapplicationoftherussianbiosimilaromalizumabinpatientswithatopicbronchialasthmaofmoderatetosevereclinicalcourses AT kakokushkin economicaspectsofapplicationoftherussianbiosimilaromalizumabinpatientswithatopicbronchialasthmaofmoderatetosevereclinicalcourses |